Financial News
Articles published by Rezolute, Inc.
Rezolute Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results and Provides Business Update
September 19, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute to Participate in Upcoming Investor Conferences
August 27, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Announces Closing of Public Offering with Approximately $60M in Gross Proceeds
June 24, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded Warrants
June 13, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
May 15, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
April 23, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
January 24, 2024
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
December 13, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute to Participate in BTIG’s 3rd Annual Ophthalmology Day
November 17, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Reports First Quarter Fiscal 2024 Results
November 13, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Announces Further Evidence of RZ358’s Efficacy in Tumor-Mediated Hyperinsulinism
October 11, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute to Participate in Upcoming Investor Conferences in September
September 06, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute KOL Event Highlights Significant Unmet Medical Need in Diabetic Macular Edema
March 23, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress
February 10, 2023
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Rezolute Announces Initiation of a Phase 2 Study of RZ402 in Patients with Diabetic Macular Edema
December 15, 2022
From Rezolute, Inc.
Via GlobeNewswire
Tickers
RZLT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.